The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
暂无分享,去创建一个
Takashi Asai | S. Jhanwar | G. Schwartz | S. Nimer | J. Nair | T. Asai | R. Comenzo | H. Landau | Stephen D Nimer | Gary K Schwartz | S. McNeely | Heather J Landau | Samuel C McNeely | Jayasree S Nair | Raymond L Comenzo | Hillel Friedman | Suresh C Jhanwar | H. Friedman | S. Mcneely
[1] K. Anderson,et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.
[2] S. Boehrer,et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. , 2001, Haematologica.
[3] E. Moler,et al. CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo , 2007, Clinical Cancer Research.
[4] G. Schwartz,et al. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] G. Zachos,et al. Chk1-Dependent S-M Checkpoint Delay in Vertebrate Cells Is Linked to Maintenance of Viable Replication Structures , 2005, Molecular and Cellular Biology.
[6] James B. Mitchell,et al. In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762 , 2010, Clinical Cancer Research.
[7] T. Therneau,et al. Clinical course of patients with relapsed multiple myeloma. , 2004, Mayo Clinic proceedings.
[8] E. Sausville,et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.
[9] D. Conrad,et al. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. , 2004, Blood.
[10] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[11] P. Hasty,et al. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage , 2008, Oncogene.
[12] A. D’Andrea,et al. Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway , 2007, Molecular and Cellular Biology.
[13] A. Gunasekera,et al. Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents* , 2003, Journal of Biological Chemistry.
[14] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[15] G. Schwartz,et al. Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe , 2004, Cancer Research.
[16] P. Moreau,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Zhivotovsky,et al. Death through a tragedy: mitotic catastrophe , 2008, Cell Death and Differentiation.
[18] K. Yamashita,et al. Cleavage-mediated Activation of Chk1 during Apoptosis* , 2008, Journal of Biological Chemistry.
[19] Stephen Green,et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.
[20] L. Cro,et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. , 1993, Blood.
[21] James B. Mitchell,et al. In Vitro and In Vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor , 2009 .
[22] Y. Pommier,et al. The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses , 2007, Molecular and Cellular Biology.
[23] H. Einsele,et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Jacques Corbeil,et al. Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents , 2008, Clinical Cancer Research.
[25] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[26] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[27] P. Richardson,et al. Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] K. Anderson,et al. Interleukin-6 Overcomes p21WAF1 Upregulation and G1 Growth Arrest Induced by Dexamethasone and Interferon-γ in Multiple Myeloma Cells , 1997 .
[29] A. Almasan,et al. Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53. , 1999, Gene expression.
[30] Y. Matsuo,et al. Guidelines for the characterization and publication of human malignant hematopoietic cell lines , 1999, Leukemia.
[31] I. Roninson,et al. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[32] P. O'Connor,et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.
[33] Jiri Bartek,et al. Checking on DNA damage in S phase , 2004, Nature Reviews Molecular Cell Biology.
[34] Y. Pommier,et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase , 2010, Cell cycle.